Predictors for Chronic Urinary Toxicity Following Treatment of Prostate Cancer with 3-D Conformal Radiotherapy: Dose-volume Analysis of a Phase II Dose Escalation Study

Asif Harsolia,Carlos Vargas,Larry L. Kestin,Di Yan,D. Brabbins,David Lockman,J LIANG,Gary Gustafson,P CHEN,F.A. Vicini

DOI: https://doi.org/10.1016/s0360-3016(04)01640-2

2004-01-01

Abstract:The relationship between chronic urinary toxicity and the dose to the volume of irradiated bladder and prostate remains unclear. We analyzed our experience treating localized prostate cancer with three-dimensional (3-D) conformal adaptive radiotherapy (RT) in our phase II dose escalation trial to identify factors predictive for chronic urinary toxicity. From 1999–2002, 331 patients with clinical stage T1-T3 (NO, MO) prostate cancer were prospectively treated with 3-D conformal RT to a median dose of 79.7 Gy to the isocenter and 75.6 Gy to the confidence limited planning target volume (cl-PTV) in 1.8 Gy fractions. A patient specific cl-PTV was constructed based on multiple CT scans. Urethrograms were done to identify the urethral beak and bladder neck. For each case, the bladder (bladder solid) was contoured (median volume: 145 cc). The bladder wall was defined as the bladder solid with a 3-mm wall thickness (median volume: 28cc). Toxicity was quantified using the NCI Common Toxicity Criteria 2.0. Multiple clinical and dose-volume endpoints were evaluated. Median follow-up was 1.6 years. The 3 year rates of grade ≥2 and grade ≥3 chronic urinary toxicity were 15% and 3.6% respectively. Thirty patients (10%) experienced grade ≥2 chronic urinary toxicity (8.2% urinary frequency, 3.1% urinary retention, 1.2% hemorrhagic cystitis, 0.8% urethral stricture, and 0.4% urinary incontinence) at a median interval of 1.2 years. Eight patients (2.3%) experienced grade ≥3 chronic urinary toxicity at a median interval of 1.1 years. One patient had grade 4 urinary toxicity. Bladder solid volume, prostate volume, cl-PTV, and the bladder wall volume were all significantly associated with urinary toxicity. The bladder wall receiving ≥30 Gy (V30) and ≥82 Gy (V82) were significant predictors for grade ≥3 chronic urinary toxicity and grade’3 chronic urinary retention (see Table). Grade ≥2 (p = 0.001) and grade ≥3 (p = 0.03) acute urinary toxicity were predictive of grade ≥2 chronic urinary toxicity. The same applied for acute grade ≥2 (p = 0.05) and ≥3 (p < 0.001) urinary toxicity being predictive for chronic grade ≥3 urinary toxicity. Bladder wall dose-volume endpoints are predictive for the development of urinary toxicity. Acute urinary toxicity is predictive for chronic urinary toxicity. Bladder wall V30 and V82 can be used to predict the risk of chronic urinary toxicity and can be used as an aid in determining optimal prostate RT dose. Our recommendations based on this data set is to attempt to limit the bladder wall V30 to <30cc and the V82 to <7cc.